Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.